A Randomised Double-Blind Placebo-Controlled Multicenter Study with Extension to Evaluate the Efficacy Safety and Tolerability of Canagliflozin in the Treatment of Subjects with Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

The study aims to compare 2 doses of canagliflozin against placebo in treating patients over 25 years of age, who have inadequately controlled type 2 diabetes and moderate renal impairment. Patients will be randomised to receive either 100mg or 300mg of canagliflozin or placebo for 26 weeks, in addition to their current diabetes medication, with a possibility of continuing for an additional 26 weeks. The study is blinded so neither the patients nor the site staff will know what the patient is taking and there is an equal change of receiving the different doses of canagliflozin or placebo. The study will asses patients for how well their diabetes is controlled on the study and also assess any side effects they have whilst taking study medication. In order to achieve this patients will have to attend regular clinic visits intially every 3 weeks then 6 - 8 weekly for first 26 weeks. In the second 26 weeks there are only 2 visits 18 weeks apart. During these visits blood samples will be taken and analaysed and patients will be asked how they feel and this will all be recorded on a case report form. Patients will also be asked to complete a diary during the study, recording their blood sugar levels (taken on a monitor provided by the sponsor), any problems they have between visits and when they take their study medication.